Bank of New York Mellon’s Corvus Pharmaceuticals CRVS Stock Holding History

Bank of New York Mellon’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.03M	Buy	202,609 +17,262	+9%	+$240K	﹤0.01%	2715
2026 Q1	$2.71M	Buy	185,347 +53,719	+41%	+$857K	﹤0.01%	2662
2025 Q4	$1.01M	Buy	131,628 +5,100	+4%	+$40.2K	﹤0.01%	3228
2025 Q3	$933K	Buy	126,528 +15,840	+14%	+$81.1K	﹤0.01%	3247
2025 Q2	$443K	Buy	+110,688	New	+$403K	﹤0.01%	3574
2024 Q1	–	Sell	-21,219	Closed	-$37.3K	–	4192
2023 Q4	$37.3K	Hold	21,219	–	–	﹤0.01%	4183
2023 Q3	$31K	Hold	21,219	–	–	﹤0.01%	4212
2023 Q2	$48.6K	Buy	+21,219	New	+$44.1K	﹤0.01%	4182
2019 Q2	–	Sell	-36,916	Closed	-$149K	–	4224
2019 Q1	$149K	Sell	36,916 -183	-0.5%	-$772	﹤0.01%	3939
2018 Q4	$136K	Sell	37,099 -175	-0.5%	-$1.19K	﹤0.01%	3919
2018 Q3	$320K	Buy	37,274 +175	+0.5%	+$1.75K	﹤0.01%	3804
2018 Q2	$407K	Buy	37,099 +9,782	+36%	+$109K	﹤0.01%	3718
2018 Q1	$315K	Sell	27,317 -458	-2%	-$4.33K	﹤0.01%	3780
2017 Q4	$288K	Sell	27,775 -85	-0.3%	-$1.09K	﹤0.01%	3819
2017 Q3	$444K	Sell	27,860 -1,118	-4%	-$15.5K	﹤0.01%	3633
2017 Q2	$351K	Buy	28,978 +13,023	+82%	+$139K	﹤0.01%	3752
2017 Q1	$331K	Buy	+15,955	New	+$250K	﹤0.01%	3718

Other funds holding CRVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

FMI

F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Bank of New York Mellon's CRVS Position: Q2 2026 in Review

Bank of New York Mellon increased its Corvus Pharmaceuticals (CRVS) stake by 9.3% in Q2 2026, buying an estimated $240K and bringing the position to 202,609 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2715.

Bank of New York Mellon first reported a position in CRVS in Q1 2017 and has held it in 17 quarters since. 69 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Bank of New York Mellon held 202,609 shares of Corvus Pharmaceuticals worth $3.03M as of Q2 2026.
Bank of New York Mellon bought 17,262 Corvus Pharmaceuticals shares in Q2 2026, an estimated $240K.
Corvus Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2715 holding.
Bank of New York Mellon first reported a position in Corvus Pharmaceuticals in Q1 2017 and has held it in 17 quarters since.
69 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.